Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises DoubleVerify Holdings, Inc. ("DoubleVerify" or the "Company") (NYSE: DV) investors of a class action representing investors that bought securities between November 10, 2023 and February 27, 2025, inclusive (the "Class Period"). DoubleVerify investors have until July 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

Core Viewpoint - Red Cat Holdings, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its production capacity and the value of its contracts, leading to significant stock price declines during the class period from March 18, 2022, to January 15, 2025 [1][3][4][5][6]. Group 1: Company Operations and Financial Performance - Red Cat Holdings provides products and solutions for the drone industry, including the "Teal 2" drone designed for nighttime military operations [3]. - The company overstated the production capacity of its Salt Lake City facility, claiming it could produce 1,000 drones per month, while it was only capable of producing 100 drones per month at the time of disclosure [4]. - In the first quarter of fiscal year 2025, Red Cat reported a loss of $0.17 per share, missing expectations, and generated $2.8 million in revenue, falling short by $1.07 million [5]. - The company paused manufacturing of the Teal 2 and delayed prototype builds for the U.S. Army, which directly impacted sales [5]. Group 2: Stock Price Impact - Following the disclosure of the actual production capacity on July 27, 2023, Red Cat's stock price fell nearly 9% [4]. - After the disappointing financial results reported on September 23, 2024, the stock declined over 25% [5]. - A report published by Kerrisdale Capital on January 16, 2025, questioned the feasibility of the SRR contract and led to a stock decline of more than 21% over the following two trading sessions [6].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during a defined class period [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [2]. - Investors are encouraged to contact the Schall Law Firm before August 25, 2025, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Hims & Hers made false and misleading statements regarding its marketing practices, particularly in relation to the promotion of products that could jeopardize patient safety [4]. - The company faced the risk of having its partnership with Novo Nordisk terminated due to these deceptive marketing activities [4]. - The misleading public statements resulted in financial damages to investors once the truth about the company's practices was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 7, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4] Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements about strong visibility into customer demand [5] - The lawsuit also highlights operational inefficiencies that diluted profit margins and the risk of costly restructuring activities, including exiting contracts with long-standing customers [5]

PHILADELPHIA, June 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) on behalf of purchasers of Compass securities between May 1, 2024 through May 7, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Compass securities during the Class Period may, no later than JULY 8, 2025, seek to be appointed as a lead plaintiff rep ...

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

Core Viewpoint - PepGen Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, during a specified period [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [2][3]. - Investors are reminded of an upcoming deadline to file as lead plaintiff by August 8, 2025, which allows them to represent other class members in the litigation [3]. Group 2: Legal Representation - Bernstein Liebhard LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. - The firm has a strong track record, having recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its litigation success [5].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive. For more information, submit a form at Sarepta Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb. ...

The US Supreme Court agreed to consider shielding Cox Communications from a $1 billion lawsuit by the music industry https://t.co/yCQZSnpfyN ...

NEW YORK, June 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Compass Group Diversified Holdings, LLC (NYSE: CODI).Shareholders who purchased shares of CODI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/compass-diversified-loss-submission-form/?id=154633&from=4CLASS PER ...